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Abstract
Background: Novel therapeutic agents that selectively induce tumor cell death are urgently needed in the clinical 
management of cancers. Such agents would constitute effective adjuvant approaches to traditional chemotherapy 
regimens. Organosulfur compounds (OSCs), such as diallyl disulfide, have demonstrated anti-proliferative effects on 
cancer cells. We have previously shown that synthesized relatives of dysoxysulfone, a natural OSC derived from the 
Fijian medicinal plant, Dysoxylum richi, possess tumor-specific antiproliferative effects and are thus promising lead 
candidates.
Methods: Because our structure-activity analyses showed that regions flanking the disulfide bond mediated 
specificity, we synthesized 18 novel OSCs by structural modification of the most promising dysoxysulfone derivatives. 
These compounds were tested for anti-proliferative and apoptotic activity in both normal and leukemic cells.
Results: Six OSCs exhibited tumor-specific killing, having no effect on normal bone marrow, and are thus candidates 
for future toxicity studies. We then employed mRNA expression profiling to characterize the mechanisms by which 
different OSCs induce apoptosis. Using Gene Ontology analysis we show that each OSC altered a unique set of 
pathways, and that these differences could be partially rationalized from a transcription factor binding site analysis. For 
example, five compounds altered genes with a large enrichment of p53 binding sites in their promoter regions (p < 
0.0001).
Conclusions: Taken together, these data establish OSCs derivatized from dysoxysulfone as a novel group of 
compounds for development as anti-cancer agents.
Background
The ultimate goal of drug development is to create thera-
peutic agents that kill tumor cells but spare normal cells.
Novel therapies that selectively induce tumor cell death
are urgently needed in the clinical management of can-
cers. Advances in cancer biology have revealed that
tumor cells retain their intrinsic ability to commit suicide,
known as apoptosis [1,2]. Because of this, compounds are
being developed to trigger apoptosis in a tumor-specific
manner. Triggering non-inflammatory elimination of
tumor cells by inducing them to undergo apoptosis is
highly desirable [3].
To this end, there has been interest in exploiting the
anti-proliferative effects of several natural organosulfur
compounds (OSCs), such as those found in garlic, onions
and mahogany trees [4,5]. Compounds from garlic, such
as diallyl disulfide (DADS), have been shown to have lim-
ited toxicity and reduce tumor load in vivo [6]. The anti-
proliferative mechanism is thought to involve cell arrest
in the G2/M phase of the cell-cycle. Despite these results
with natural products, chemically-synthesized OSCs
have not yet been systematically evaluated for their anti-
cancer activity. We have previously shown that synthe-
sized relatives of dysoxysulfone, a natural OSC derived
from the Fijian medicinal plant, Dysoxylum richi, also
possess antiproliferative effects on tumor cells [7,8]. A
structure-activity analysis of dysoxysulfone relatives iden-
tified three chemicals, termed compounds F, H and N,
which did not affect the viability of normal human dip-
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loid cells but killed model leukemia cell lines [7,8]. These
compounds contain a core disulfide structure similar to
DADS, and our structure-activity analysis strongly sug-
gested that regions flanking the disulfide group contrib-
ute to the specificity of cell killing. Further, these
compounds are synthesized, not extracted from natural
sources, providing a renewable, cost-effective and long-
term manner of procuring them.
Our current study extends this previous work and
attempts to determine how structure-activity relation-
ships can be exploited to increase potency of OSCs while
retaining tumor-specificity. First, we synthesized new rel-
atives of compounds F, H and N. Next, these compounds
were tested for anti-proliferative and apoptotic activity in
both normal and leukemic cells. Transcriptomic profiling
of potential lead compounds was then used to determine
mechanism of action. Finally, these compounds were
assayed for their effect on normal human bone marrow.
Our results establish these synthetic OSCs as potential
novel tumor-specific therapeutic agents.
Methods
Organosulfur Compound Synthesis
Detailed chemical synthesis and characterization are pro-
vided in Additional File 1.
Cell Culture and Cell Lines
All cell lines, OCI-AML3 (referred to hereafter as AML-
3), KK, and WI38 were assayed as asynchronously grow-
ing cells and were cultured in alpha-minimal essential
medium (α-MEM) (Princess Margaret Hospital Media
Services) supplemented with 10% fetal bovine serum
(FBS) (Sigma, St. Louis, MO) and 1% penicillin/strepto-
mycin at 37°C with 5% CO2.
Biological Testing: General Sample Preparation
Approximately 20 mg of each compound was dissolved in
ACS grade acetone (5 mL, Sigma) using a volumetric
flask. Stock solutions of the compounds were stored in
the dark at -20°C. Compounds were diluted, as indicated,
immediately prior to each experiment.
MTT Assays
MTT assays were completed as described previously [7].
Briefly, leukemic and WI38 fibroblast cells were seeded at
2.7 × 105 cells/mL and 0.67 × 105 cells/mL respectively in
96 well plates (Falcon, Mississauga, Ontario). The cells
were exposed to an acetone control and a dose range of
each compound in a total volume of 150 μL for 48 hours
and assayed in triplicate. MTT data were analyzed using
Prism 3.0 (GraphPad Software Inc., San Diego, CA) by
the Chou-Talalay method. A dose-response curve for
each compound was repeated, independently, three
times.
Fixed-PI Staining
Fixed-PI assays were completed as described previously
[7]. Briefly, 106 leukemia and 2.5 × 105 WI38 cells were
seeded in a 6 well dish and 30 mm plates, respectively
(Falcon). Cells were then exposed for 48 hours to an ace-
tone control and two concentrations of each compound.
Cell cycle parameters were measured with Cellquest soft-
ware (Becton Dickinson, San Jose, CA). Each sample was
repeated, independently, three times.
TUNEL
TUNEL assays were completed as described previously
[7]. Approximately 106 leukemia cells were seeded into a 6
well dish (Falcon). The cells were then exposed to an ace-
tone control and two concentrations of each compound
for 48 hours. Cells were then harvested and fixed with 4%
formaldehyde for 15 minutes on ice. Samples were ana-
lyzed using the Cellquest software (Becton Dickinson,
San Jose, CA). Each sample was repeated, independently,
three times.
Colony Growth Assays
Normal bone marrow from bone marrow transplant
donors was collected following informed consent accord-
ing to institutional guidelines. Mono-nucleated cells were
isolated from normal bone marrow using Percoll (Amer-
sham Biosciences). Cells were washed and re-suspended
in α-MEM supplemented with 10% FBS and 10% 5637
conditioned media. Conditioned media was prepared by
growing the 5637 cells to confluency, replacing with fresh
media and harvesting the media after three additional
days of incubation. The conditioned media was used at
10% (v/v) with aMEM +10% FBS and 1% penicillin/strep-
tomycin. Mono-nucleated cells (density: 106  cells/mL)
and AML-3 cells (density: 5 × 105 cells/mL) were exposed
to various concentrations of each compound for 48
hours. Cells were then washed, counted and live mono-
nucleated (104) or AML-3 (103) cells were plated in Meth-
ocult (StemCell Technologies, BC, Canada). Colonies
were allowed to form for 12-14 days and the number of
BFU-E and CFU-C colonies of approximately >50 cells
were counted. Numbers were normalized to solvent con-
trol.
Microarray Assays
Approximately 107 AML-3 cells were treated with ace-
tone (solvent control, 0.67% (v/v)), 180 μM H, 75 μM F, 35
μM K, 35 μM L, 100 μM N, 90 μM O, 60 μM P, 20 μM Q,
12.5 nM Taxol (Sigma) and 7.5 μM Lovastatin (Apotex).
Cells were harvested for RNA at 12 hours using Trizol
Reagent (Gibco Life Technologies). RNA was purified
and 40 μg of RNA was used to synthesize cDNA probes
and then equally aliquoted and stored at -20°C for future
experiments. A home-made reference RNA set compiledWong et al. BMC Cancer 2010, 10:351
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o f  b o t h  n o r m a l  a n d  t u m o r  c e l l  l i n e s  ( W I 3 8 ,  S K B R 3 ,
PANC1, SIHA, COLO320, HSR, SKMG5, ANBL-6, A549,
NB-4, KK, DU145, MCF-7, WM983) was used to profile
the compounds. Sample cDNA and reference cDNA were
labeled using an indirect method with Cy3 and Cy5,
respectively and hybridized at 42°C overnight onto an
OCI 1.7 K human cDNA array. Chips were washed and
then scanned using a Packard Scanner and quantified
using Imagene (v5.0). Each condition was hybridized in
triplicate.
Microarray Data Analysis
The raw Imagene quantitations were read into the R sta-
tistical environment (v2.6.2) using the limma software
package (v2.12.0). A series of quality assessments were
performed on each array to ensure spatial and distribu-
tional homogeneity - no arrays were removed from the
analysis. The array data were then normalized using the
variance-stabilizing normalization (VSN) algorithm, as
implemented in the vsn package for R (v3.2.1) using
default parameters, with the exception of an increased
iteration number of 1,000 for improved model conver-
gence [9]. General linear modeling was then used to com-
pare the expression profile of each drug treatment to that
of the acetone control. The resulting hits were then sub-
ject to an empirical Bayes moderation of the standard
error [10] and a false-discovery rate adjustment [11]. Hits
were deemed differentially expressed relative to control
when padjusted < 0.05. Each spot on the array was re-anno-
tated using a BLAST pipeline. Briefly, the sequence for
each spot was BLASTed against the reference sequences
for UniGene build Hs.199 using blastn with default
parameters except for an expectation of 0.0001 and a
word-size of 7, chosen to increase sensitivity of the analy-
sis [12]. For each spot, the UniGene cluster with the high-
est sequence-similarity was selected as representative.
UniGene clusters were then mapped to Entrez Gene IDs
using annotation downloaded from NCBI on 2007-02-08.
Data were clustered using divisive hierarchical algorithm
DIANA with Pearson's correlation as the similarity met-
ric, as implemented in the cluster package (v1.11.9).
Heatmaps were visualized using the lattice package
(v0.17-6). Thresholds for cluster analysis were selected
using the F statistic from the general-linear model fit. A
series of thresholds were selected to ensure that results
were parameter-independent.
Gene ontology (GO) enrichment analysis employed the
GOMiner software [13], using all human databases, all
look-up options, all evidence codes, and all three GO
ontologies. False-discovery rates were estimated using
the maximum 1,000 permutations, and a threshold of 0.1
was used to select terms. A separate GO analysis was per-
formed for each compound, and the results were merged
in a database to create a matrix with GO-terms as rows
and compounds as columns. This matrix was subjected to
divisive hierarchical clustering using the DIANA algo-
rithm with Pearson's correlation as the similarity metric,
as implemented in the cluster package (v1.11.9). Heat-
maps were visualized using the lattice package (v0.17-6).
Clustering was performed on subsets of this matrix
selected based on cumulative probability thresholds,
where the cumulative probability was calculated as the
product of the probabilities for each compound. Missing
values were treated as having a probability of 1.0 at this
step. A series of thresholds were selected to ensure that
results were insensitive to perturbations in this parame-
ter.
To determine if the observed changes in mRNA abun-
dance were indicative of altered transcription factor
activity, we performed transcription factor binding site
(TFBS) enrichment analysis. Briefly, for each compound,
we identified the set of genes exhibiting altered mRNA
abundances at padjusted < 0.05. For each gene we extracted
2001 bp of regulatory sequence, centered on the TFBS,
using build hg18 of the human genome and the genomic
positioning annotation provided by the UCSC Genome
Browser Database in the REFFLAT table on 2007-04-07
[14]. We used a library of 123 TFBS motifs [15] and the
CLOVER software package [16] to scan these regulatory
regions and to identify TFBS motifs that were enriched or
depleted. To ensure statistical robustness we employed
three separate permutation controls. We used standard
mono- and di-nucleotide randomization. Additionally,
we extracted the regulatory regions for all genes on the
microarray and used these as a background dataset. Each
permutation experiment was run 10,000 times, and only
those TFBSs showing enrichment or depletion at p < 0.05
(for enrichment) or p > 0.95 (for depletion) by all three
tests were included in the final results.
Results
Synthetic Considerations
Structural details for the relatives of F, H, and N prepared
and tested for this study are provided in Additional File 2
and Additional File 3, Figure S1. Unsymmetrical disul-
fides were constructed by condensation of an appropriate
sulfenyl chloride and mercaptan pair. Sulfenyl chlorides
w e r e  f r e s h l y  p r e p a r e d  f r o m  s y m m e t r i c a l  d i s u l f i d e s  o r
from unsymmetrical methyl disulfides in accord with the
detailed discussion offered earlier [17]. Most ester prepa-
rations used commercial methyl thioglycollate as the
mercaptan. β-Sulfone disulfide preparations required one
of the β-mercaptosulfones 1 or 2.
RSO2CH2CH2SH
1 R = p-CH3(C6H4)
2 CH3Wong et al. BMC Cancer 2010, 10:351
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The mercaptan 1 was known [18]. The mercaptosul-
fone 2 was prepared from a symmetrical starting material
as outlined in Figure 1.
Relatives of lead active OSCs reduce proliferation of 
leukemic cells
To assess the new compounds for tumor-specific anti-
proliferative activity both leukemic and non-transformed
human diploid fibroblast cell lines were exposed to
increasing concentrations of OSCs and assayed for prolif-
eration using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay [19]. The MTT
assay measures the ability of cellular mitochondrial dehy-
drogenase to convert the yellow MTT substrate to a pur-
ple formazan product. From our previous work, the
MTT50 values for compounds K-Q were similar across
the panel of cell lines. Accordingly, we selected a repre-
sentative leukemic cell line, AML-3, for subsequent MTT
assays and used a non-transformed diploid cell line of
fibroblast origin, WI38, as a control. A comparison of the
MTT50  values between normal (WI38) and leukemic
(AML-3) cells show that many compounds induce differ-
ential responses (Additional File 4 and Figure 2A), with
enhanced activity in leukemic cells compared to normal
cells being most common (values above the y = x line in
Figure 2A). The MTT assays segregated the compounds
into three clear and distinct groups (Figure 2A). Group I
compounds (F2, F3 and H1) possessed little to no anti-
proliferative activity at the concentrations tested (Figure
2B). Group II compounds (F1, H2, H5, H6, and N2)
decreased proliferation of AML-3 but not of WI38 cells
(Figure 2C). Based on our previous analyses, compounds
F, H, K, L, N, O, P and Q are also classified in group II [8]
The chemical composition of these previously evaluated
compounds is provided in Table 1 for comparison. Group
III compounds (F4, F5, F6, F7, F8, H3, H4, H7, H8, and
N1) decreased proliferation of both AML-3 and WI38
cells to varying degrees (Figure 2D). Thus, the MTT assay
indicates compounds in group II have anti-proliferative
activity specific to leukemic cell lines, while compounds
in group III have anti-proliferative activity that affects
both normal cells and tumor cells, but to different
degrees. This MTT study shows that relatives of F, H and
N are more potent than the parental structure.
OSCs induce changes in cell cycle and apoptosis
To determine whether the observed anti-proliferative
activity was a consequence of elevated apoptosis, both
leukemic (AML-3 and KK) and non-transformed fibro-
blast (WI38) cells were exposed to OSCs at two concen-
trations for 48 hours. We evaluated the proportion of
apoptotic cells in leukemic and normal cell lines by fixed-
PI (Figure 3B and Additional File 3, Figure S2A) and ter-
minal deoxynucleotidyl transferase-mediated
dUTP\nicked-end-labeling (TUNEL) (Figure 3C and
Additional File 3, Figure S2B) assays. The combined
results of these experiments are provided in Additional
File 5. As expected, compounds from group I were bio-
logically inactive and did not affect apoptosis in any cell
line, as assayed by both fixed-PI and TUNEL (Additional
File 5 and Figure 3), confirming the MTT assay. Group II
compounds, with the exception of F1, preferentially
induced apoptosis in leukemic cells over normal diploid
cells (Additional File 5 and Figure 3). Compound F1
induced apoptosis in a concentration dependent manner
in both leukemic and normal diploid cells, despite the dif-
ference in anti-proliferation shown by the MTT assay.
TUNEL experiments independently confirmed the leuke-
mic cells were undergoing apoptosis from each phase of
the cycle upon exposure to compounds F1, H2, H5 and
H6 (Additional File 5, Figure 3).
Interestingly, as demonstrated previously for com-
pounds K, L, N, O, P and Q, some OSCs (H2, H5 and H6)
changed the cell cycle profile of the WI38 cells, with an
accumulation of cells in the G2/M phase of the cell cycle,
suggesting that OSCs can trigger G2 cell cycle arrest in
non-transformed cells (Figure 3A and data not shown).
Compounds from group III could be classified into two
distinct groups based on their cell cycle profiles in leuke-
mic and normal cells (Figure 3C). Compounds H3, H7,
and N1 increased the percentage of cells in the pre-G1
region for both leukemic and normal diploid cells but
were more toxic to leukemic cells (Additional File 5).
These compounds caused leukemic cells to stain TUNEL
positive in all phases of the cell cycle. In direct contrast, at
the concentrations tested, the remaining compounds (F4,
F5, F6, F7, F8, H4 and H8) similarly induced apoptosis in
both the leukemic cell lines and the normal diploid cells
(Additional File 5 and Figure 3). Apoptosis was confirmed
in the leukemic cell lines by TUNEL staining at the con-
centrations used and counterstained with PI to examine
cell cycle profile (Additional File 5). Of the compounds
tested in group III, only compound F6 caused an increase
in the number of cells in the G2/M phase of the cell cycle
(Figure 3).
Figure 1 Preparation of β-mercaptosulfone 2. Schematic represen-
tation of the synthesis of β-mercaptosulfone 2.Wong et al. BMC Cancer 2010, 10:351
http://www.biomedcentral.com/1471-2407/10/351
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Based on the combined results from the MTT, fixed-PI
and TUNEL assays we grouped OSCs into the following
categories. Group I, inactive compounds are F2, F3 and
H1. Group II, tumor-selective agents are compounds F1,
H2, H5, H6, N2 as well as compounds F, H, K, L, N, O, P
and Q from our previous work [7,8]. Group III com-
pounds, which do not exhibit tumor-specific activity like
compound M from our previous study, are compounds
F4, F5, F6, F7, F8, H3, H4, H7, H8, and N1.
Expression profiling segregates OSCs into mechanistic sub-
classes
We performed cDNA microarray analysis to evaluate the
mechanisms by which OSCs induce tumor-specific apop-
tosis. AML-3 cells were exposed to compounds from
group II - F (75 μM), H (180 μM), L (35 μM), K (35 μM),
N (100 μM), O (90 μM), P (60 μM), and Q (20 μM). Con-
centrations were selected that induce approximately 20-
30% apoptosis in 48 hours as determined by the TUNEL
assay (data not shown). To capture the molecular events
occurring prior to apoptosis, cells were harvested after 12
hours of exposure and RNA was extracted. As positive
controls for apoptosis, two other compounds were ana-
lyzed: lovastatin and taxol. Lovastatin is a well-known
treatment for hypercholesterolemia and has been identi-
fied as a tumor-specific inducer of apoptosis [20]. Taxol is
a chemotherapeutic agent that induces apoptosis in the
G2/M phase of the cell cycle [21].
We used a rigorous quality-control assessment of each
array (Additional File 3, Figure S3) and pre-processed the
data using standard techniques. For each compound,
general linear-modeling was used to identify specific
genes whose mRNA abundances were significantly
Figure 2 Proliferation rates of leukemia and normal cells exposed to OSCs. We measured the biological activity of OSCs in normal fibroblast dip-
loid (WI38) and leukemic (AML-3) cells using the MTT assay. (A) Differential activity was observed for a subset of compounds. Group I compounds (F2, 
F3, and H1) are biologically inactive, Group II compounds (F1, H2, H5, H6 and N2) reduce proliferation in leukemic cells only and Group III compounds 
(F4, F5, F6, F7, F8, H3, H4, H7, H8 and N1) affect proliferation of both leukemic (AML-3) and normal, non-transformed cells (WI38) to varying degrees. 
(B-D) Representative analyses of compounds from each group: each compound was assayed in three independent experiments. AML-3 cells are 
shown with squares; WI38 cells are shown with triangles.Wong et al. BMC Cancer 2010, 10:351
http://www.biomedcentral.com/1471-2407/10/351
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Table 1: Colony growth of leukemia cells and normal bone marrow in response to treatment with organosulfur 
compounds
Group Compound Name Structure Dose (μM) Selectivity
AML NBM
IF 2 C H 3SO2CH2CH2SSCH2CH2SO2CH3 ND
F3 CH3SO2CH2CH2SSPh ND
H1 CH3OC(O)CH2CH2SSCH3 ND
II F CH3SO2CH2CH2SSCH3 100 ++ +
F1 CH3SO2CH2CH2SSCH2CO2CH3 100 +++ +
HC H 3OC(O)CH2SSCH3 175 ++ -
H2 CH3OC(O)CH2SSCH2CH2CH3 50 ++ +
H5 CH3OC(O)CH2SS(CH2)6CH3 200 +++ -
H6 CH3(CH2)5OC(O)CH2SSCH2CH2CH3 50 + +
KC H 3SO2CH2SSCH2CH2CH2CH2CH3 50 +++ ++
LC H 3SO2SPh 50 ++ -
NC H 3SCH2SSCH3 100 ++ -
N2 CH3SCH2SSCH2CH2CH2SO2CH3 50 ++ +
OC H 3OC(O)CH2SSCH2C(O)OCH3 100 ++ -
P PhC(O)CH2SSCH3 100 ++ -
Q PhSSCH2OC(O)CH2CH3 50 ++ ++
III F4 CH3SO2CH2CH2SS(C6H4)OCH3 20 ++ +
F5 CH3SO2CH2CH2SS(C6H4)NO2 20 +++ +++
F6 CH3(C6H4)SO2CH2CH2SSCH3 40 +++ +++
F7 CH3(C6H4)SO2CH2CH2SSPh 30 ++ +Wong et al. BMC Cancer 2010, 10:351
http://www.biomedcentral.com/1471-2407/10/351
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altered (padjusted < 0.05) relative to the acetone control;
complete results are presented in Additional File 6.
The number of genes affected by each compound varies
across several orders of magnitude (F igure 4A). A t the
concentrations and time-points selected both compound
F and taxol significantly alter the mRNA levels of tens of
genes whereas compounds N and K alter hundreds.
Compounds with similar mRNA profiles might share
mechanisms of action. Differentially expressed genes
(punadjusted < 10-12; F-test) were subjected to unsupervised
pattern recognition (Figure 4B) [22]. Three groups of
compounds exist as defined by the ratio of within-cluster
to between-cluster distances: one containing compounds
N, O, and P; one containing compounds H, K, and Q; and
one containing compound F along with lovastatin and
taxol; compound L is an outlier. We verified the parame-
ter-independence [23] of our analysis by varying the p-
value threshold from 10-3 to 10-12 (Additional File 3, Fig-
ures S4-S6).
Knowing that the OSCs induced compound-specific
changes in mRNA abundance profiles, we sought to
determine if these changes could be related to specific
fu n ct i o n a l  pa t h wa ys  u s i n g  g e n e  o n t o l o gy  ( GO )  e n ri c h -
ment analysis. This involves determining if the genes
whose mRNA abundances are significantly altered (pad-
justed < 0.05) are enriched for specific functional annota-
tions relative to the array as a whole. A well-established,
publicly available algorithm and implementation were
used for this analysis [13]. For each compound we identi-
fied a set of functional annotations that were enriched.
Selected enriched GO terms are given in Table 2 (the
complete list is available as Additional File 7).
Having determined that the compounds could be
grouped according to their mRNA abundance profiles,
we hypothesized that these groups could be recapitulated
from their pathway profiles. We used the log10|P| values
f r o m  t h e  G O  e n r i c h m e n t  a n a l y s i s  f o r  t e r m s  s h o w i n g
enrichment at Pcumulative < 10-10 to group compounds
using divisive hierarchical clustering (Figure 4C). Path-
way-based clustering yielded nearly-identical patterns of
mRNA-profile-based clustering (compare Figures 4B and
4C), with the exception of compound N. To verify this
finding statistically we calculated the Rand and Adjusted
Rand indices. These metrics give a direct assessment of
similarity between the two clustering profiles, with values
of one indicating identical clusters and values of zero
indicating random-chance similarity. The Rand-Index
between mRNA- and GO-derived groupings was 0.89
while the Adjusted Rand-Index was 0.67, verifying the
similarity. We again ensured the stability of our clustering
patterns by varying the threshold used to select GO terms
across several orders of magnitude (Additional File 3, Fig-
ures S7-S9).
Our microarray data identified both specific genes and
specific functions altered by each OSC. We hypothesized
that alterations in mRNA abundances (and hence altera-
tions in functional profiles) are regulated, in part, by spe-
cific transcription factors. To test this, we analyzed
transcription factor binding site (TFBS) enrichment [24].
F8 CH3(C6H4)SO2CH2CH2SSCH2CH2SO2(C6
H4)CH3
20 +++ ++
H3 CH3OC(O)CH2SS(C6H4)OCH3 ND
H4 CH3OC(O)CH2SSPh 25 + -
H7 CH3(CH2)5OC(O)CH2S SPh 25 + -
H8 CH3OC(O)CH2SS(C6H4)NO2 ND
MO 2N(C6H4)SSCH3 50 +++ +++
N1 CH3SCH2SSCH2SCH2SO2CH3 50 +++ +++
Results of compounds assayed for specificity and sensitivity to leukemic cell lines and normal bone marrow using colony growth assay. The 
colony growth assay results for compounds K, L, M, N, O, P and Q were repeated a minimum of three independent times with consistent 
results. Colony growth assay results for the remaining compounds were repeated twice. Data is summarized as the fraction of colonies 
formed compared to solvent controls, and indicated as >0.75 (-, no effect), 0.75 (+), 0.50 (++), and >0.25 (+++). Compounds with tumor-
specific activity are shaded. Abbreviations: AML, Acute Myelogenous Leukemia; NBM, normal bone marrow; ND, not determined
Table 1: Colony growth of leukemia cells and normal bone marrow in response to treatment with organosulfur 
compounds (Continued)Wong et al. BMC Cancer 2010, 10:351
http://www.biomedcentral.com/1471-2407/10/351
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Figure 3 The effects of OSCs on cell cycle profile and apoptosis. A) The first two columns show representative cell-cycle profiles in normal WI38 
and leukemic AML-3 cells after 48 hours of exposure to OSCs from each group (F2 at 200 μM, H5 at 200 μM, F6 at 80 μM). Cells were stained with 
propidium iodide and analyzed by flow cytometry. The percentage of cells staining in the pre-G1 region (apoptotic) is displayed in the upper left cor-
ner of each histogram. The third column shows TUNEL staining of leukemic KK cells after 48 hours of exposure to OSCs (F2 200 μM, H5 200 μM, F6 40 
μM). The percentage of cells staining TUNEL positive (apoptotic) is displayed in the top right quadrant. B) The mean percentage of cells staining in 
pre-G1 region (apoptotic) was determined for AML-3 and WI38 cells. The ratio of these two values for each OSC is a proxy for their therapeutic ratio. 
A similar analysis was performed for KK cells (Additional File 1 Figure S2A). C) The mean percentage of cells staining TUNEL positive (apoptotic) was 
determined for each OSC in both KK and WI38 cells. The ratio of these two values is a proxy for their therapeutic ratio. A similar analysis was performed 
for AML-3 cells (Additional File 1 Figure S2B).Wong et al. BMC Cancer 2010, 10:351
http://www.biomedcentral.com/1471-2407/10/351
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This analysis identified 38 specific DNA sequence motifs
that are enriched in genes responsive to one or more
compounds (Additional File 8). The average motif was
enriched in 3 ± 2 compounds, indicative of very different
transcriptional regulatory networks.
Some patterns of TFBS enrichment are suggestive of
mechanisms of apoptosis. For example the p53 binding
site was enriched amongst genes dysregulated by five
compounds (K, L, N, P, and Q). Given its powerful pro-
apoptotic role, these data might indicate p53-mediated
apoptosis. Similarly, the target genes of compound O
Figure 4 Microarray profiling of OSCs identifies mechanistic groups. (A) Microarray analysis of changes in mRNA abundance induced by 8 OSCs 
and two control compounds identifies that some compounds induce significantly greater alterations than others. (B) These profiles of changes in 
mRNA abundances can be used to clusters the compounds using a divisive hierarchical algorithm (colour bars represent fold-change relative to ace-
tone control). (C) Mapping altered mRNA profiles to functional groups allows clustering of compounds based on their functional profiles (colour bars 
represent -log10|P|). (D) To assess the mechanistic underpinnings of altered mRNA abundance profiles we performed transcription factor binding site 
analysis, and clustered compounds into mechanistic groups (colour bars represent -log10|P|, labels indicate difference TFBS IDs). Intriguingly, the 
mRNA abundance, GO functional, and TFBS mechanistic results allow clustering of the data into similar, but non-identical groups.Wong et al. BMC Cancer 2010, 10:351
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were depleted for binding sites of the growth-promoting
E2F family of transcription factors.
To determine if patterns of transcriptional regulation
could be used to group compounds we subjected the set
of enriched TFBSs to divisive hierarchical clustering (Fig-
ure 4D). Interestingly, while GO analysis led to a similar
organization of compounds compared to mRNA data
alone (Figure 4 parts B and C), TFBS analysis did not. The
adjusted Rand-index between the TFBS clustering and
the mRNA based clustering was 0.0, and between the
TFBS clustering and the GO clustering was only 0.1 - dra-
matically lower than the 0.7 concordance between mRNA
and GO clusters. Although TFBS is a relatively limited
technique for probing transcriptional regulatory net-
works, these data suggests that different compounds per-
turb a common set of biological pathways, but by
different regulatory mechanisms.
Six OSCs preserve normal myeloid progenitor colony 
formation
To determine the potential of progenitor cells to repopu-
late the hematopoietic system after exposure to OSCs we
employed colony growth assays. Normal bone marrow
was exposed to various doses of OSCs for 48 hours,
washed, and counted. Simultaneously, an equivalent
number of cells were plated in methylcellulose supple-
mented with growth factors, without any OSC exposure.
After 12-14 days colonies of myeloid progenitors were
counted, normalized to the solvent control and compared
to the colony forming potential of similarly treated AML-
3 cells. Due to a limited availability of normal bone mar-
row, group I (inactive) compounds were not assayed. Two
concentrations were used when possible to determine if
the compound was truly selective for leukemic cells.
Of the group II compounds (compounds F, F1, H, H2,
H5, H6, K, L, N, N2, O, P and Q), seven (F, F1, H2, H6, K,
N2 and Q) reduced the proliferative potential of normal
myeloid progenitors (Table 1) and thus have evidence for
normal bone marrow toxicity. Importantly, six OSCs
(compounds H, H5, L, N, O and P) did not markedly
reduce the proliferative potential of normal myeloid pro-
genitors, providing further evidence of their tumor speci-
ficity.
Group III compounds (F4, F5, F6, F7, F8, H4, H7, and
N1) were used at lower concentrations than in previous
assays to confirm our findings that these compounds
were acting as general cytotoxins. Colony growth assays
of group III compounds showed equivalent reduction of
colony forming potential in leukemic and normal bone
marrow, corroborating our previous findings (Table 1).
Discussion
Our previous work identified organosulfur compounds
derived from a Fijian medicinal plant, Dysoxylum richi, as
potential tumor-specific anti-proliferative agents. A
structure-activity analysis identified groups adjacent to
the disulfide bond as being important mediators of
tumor-specificity. Accordingly, we set out to design and
synthesize novel relatives of the most effective previously
tested compounds. We then tested those compounds for
Table 2: Selected top enriched GO terms
ID Term F H K L N O P Q Lova Taxol
GO:0003723 RNA Binding 0.0 1.2 3.0 0.3 1.9 0.4 0.1 7.2 0.2 0.0
GO:0006412 Translation 0.0 1.2 4.4 1.1 5.1 0.4 0.7 5.8 1.2 0.0
GO:0045765 Regulation of angiogenesis 0.0 0.0 1.1 1.1 1.1 3.7 0.2 1.4 0.3 0.0
GO:0030162 Regulation of proteolysis 0.0 0.0 1.2 0.4 0.3 0.0 0.0 0.7 3.6 0.0
GO:0043122 Regulation of I-kappaB kinase 
NF-kappaB cascade
0.0 0.0 0.6 3.3 0.4 0.0 0.4 0.0 1.3 0.0
GO:0046870 Cadmium ion binding 0.0 0.0 0.0 0.5 1.3 3.1 0.0 0.8 0.0 2.3
GO:0006935 Chemotaxis 1.8 0.5 2.0 0.4 1.5 0.9 1.5 0.7 2.9 1.3
Genes that were differentially expressed (padjusted < 0.05) by each compound were subjected to Gene Ontology enrichment analysis using the 
GOMiner tool with 1,000 permutations. The -log10|P| for selected GO terms are shown here. For example, genes annotated as being involved in 
RNA binding are enriched amongst those differentially expressed by compound Q with p < 10-7.2 and amongst those differentially expressed by 
compound H with p < 10-1.2.Wong et al. BMC Cancer 2010, 10:351
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anti-proliferative and apoptosis-inducing ability in both
normal (albeit of fibroblast rather than hematopoietic
origin) and tumor cells. Finally, we performed microarray
analysis to map the pathways regulated by each com-
pound.
To characterize these novel organosulfur compounds
we first assayed for anti-proliferative activity using the
MTT assay over a wide range of concentrations. These
assays were performed in both normal and tumor cells to
ensure tumor-specificity. We then tested compounds for
apoptotic potential using two distinct approaches: fixed-
PI and TUNEL. These assays allowed assessment of the
effects of each OSC on cell cycle progression. Finally, for
selected compounds we used colony growth assays with
normal human bone marrow to verify tumor-specificity
in a more physiological model system.
Combining the results from these different assays, the
18 novel compounds fall into three groups. First, three
compounds were biologically inactive (F2, F3, and H1).
Second, five compounds showed some tumor-specific
induction of apoptosis (F1, H2, H5 H6, and N2),. Finally,
the remaining ten compounds (F4, F5, F6, F7, F8, H3, H4,
H7, H8 and N1) induced apoptosis with little or no selec-
tivity between tumor and normal cells. It should be noted
that these findings are potentially dose-dependent: bio-
logically inactive compounds may show activity at higher
concentrations than employed here.
Apoptosis induced by some disulfide-containing com-
pounds, such as ajoene, diallyl disulfide or dithiosulfi-
nates, are under investigation. Some studies have been
associated with the induction of reactive oxygen species,
inhibition of metabolic enzymes, DNA modification and
cell signal disruption [4,25,26]. The mechanism by which
the novel OSCs induce apoptosis is currently unknown,
and so we performed a microarray study to address this
issue. Our microarray analyses assessed eight OSCs and
two control substances, taxol and lovastatin, at a single
dose and with triplicate measurements. Our analysis of
this dataset found great variability in the number of genes
w h o s e  m R N A  l e v e l s  w e r e  a l t e r e d  b y  e a c h  c o m p o u n d .
S o m e  c o m p o u n d s ,  l i k e  F  a n d  T a x o l ,  o n l y  a l t e r e d  t h e
expression of a few genes at the doses used; other com-
pounds, like N and K, altered the expression of hundreds
of genes.
To test if the mRNA changes induced by different com-
pounds represent distinct functional groups we employed
a gene-ontology functional analysis. Clustering of func-
tional profiles (Figure 4C) led to a similar hierarchical
organization to that found by clustering the raw expres-
sion profiles (Figure 4B). Several key biological processes
were identified as dysregulated by this analysis. For exam-
ple, compounds K, N, and Q all perturbed the expression
of a large number of genes involved in translation. By
contrast, lovastatin dysregulated genes involved in prote-
olysis and compound L dysregulated genes annotated as
being positive regulators of the I-kappa-B kinase NF-
kappa-B cascade. These results provide insight into the
specific intra-cellular mechanisms of each compound.
The fact that specific functional groups were perturbed
by each compound suggested that the compounds might
be altering the activity of specific transcription factors,
either directly or indirectly through feedback loops. To
test this hypothesis we employed TFBS enrichment anal-
ysis [24] using a database of 130 known TFBS motifs. Sev-
eral binding site motifs were enriched in a compound-
specific manner, including strong enrichment of the
PPAR-gamma motif in genes regulated by compound H.
Intriguingly, genes dysregulated by compounds K, L, N, P
and Q were enriched for p53 binding sites, suggesting
these compounds may induce p53-dependent apoptosis.
Combined, we synthesized 18 novel organosulfur com-
pounds, beginning with CO-linked α-ester and α-sulfone
disulfides [27]. A good structure-activity correlation was
observed for the assumption that these compounds
behave as activated electrophiles (see Figure 5) that react
selectively with biochemically-significant thiol moieties.
The successful application of the rationale presented in
Figure 5 not only led to the design of esters and sulfones
having substantially enhanced antifungal activity [28] but
also permitted the extension of our bioactive organosul-
fur compounds to include two new classes i.e. aryl methyl
disulfides (e.g. M) and structurally related thiosulfonates
(e.g. L). Subsequent work established that selected disul-
fides showed promise as agents with antileukemic activity
[7,8], antimalarial activity [29], antithrombotic activity
[30,31] and inhibitory activity against phagocytosis of
anti-Rh(D)-coated red blood cells [32,33]. Despite its util-
ity in our previous OSC studies, our new data for com-
pounds F1 T F8 and H1 T H8 suggest that the rationale in
Figure 5 is mechanistically incomplete. To that end, the
following points are salient. (i) All of the compounds with
tumor-specific activity (F1, H2, H5, H6) are CC-linked α-
ester disulfides. (ii) The compounds with the highest
therapeutic indices have longer alkyl substituents (i.e.
Figure 5 Structure-activity model for the synthesis of novel or-
ganosulfur compounds.Wong et al. BMC Cancer 2010, 10:351
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H5). (iii) The CC-linked β-ester disulfide (H1) is inactive.
(iv) Aggressive SS activation in accord with the Figure 5
view leads to a loss of selectivity (i.e. H8 vs. H). Longer
alkyl substituents (C3 T C7) enhance lipophilicity for the
α-ester disulfides which enhances intracellular transport.
Somewhat diminished activity for H6 (compared to H5),
when the alkyl group is moved from sulfenyl sulfur to
ester oxygen, hinders approach to the carbonyl carbon,
suggesting that it may be serving as an electrophile. A
proposed chemical mechanism that accounts for the fore-
going points is presented in Figure 6.
Both thioformaldehyde and sulfenic acids are well-
known traps for mercaptide anions and would act to
sequester biochemically significant SH groups. Note that
the proposed internal attack of a disulfide sulfenyl sulfur
on the peroxide linkage (step 2, Figure 6) goes through a
favorable 6-membered transition state. Application of the
Figure 6 mechanism to the β-ester disulfide H1 would
require the corresponding internal attack to proceed
through an unfavorable 7-membered transition state,
thus accounting for the inactivity of H1. Moreover, the
proposed function of the carbonyl group in coordinating
a peroxy anion leads one to expect superior efficacy for
the α-ketodisulfide, P in accordance with our microarray
observations. Overall, we believe this proposed mecha-
nism of action accounts for our observed structure-activ-
ity results. Moreover, it serves as a platform from which
future synthetic targets can be modelled. In future studies
it will also be valuable to evaluate how other structural
factors, such as lipophilicity, alter the biological activity
of OSCs. Our previous structure-activity studies identi-
fied several promising OSCs (F, H, K, L, N, O, P and Q).
These molecules were all classified as tumor-selective
group II compounds.
Conclusions
In this manuscript we have characterized the anti-prolif-
erative effects of 18 newly synthesized OSCs, and identi-
fied an additional five group II compounds (F1, H2, H5,
H6, N2). Combined, we believe H, H5, L, N, O and P
show the most promise. These six OSCs were able to
induce apoptosis and reduce colony formation of leuke-
mic cells. Importantly, they had little effect on colony for-
mation of normal myeloid progenitor cells, suggesting
that they have a therapeutic window of activity. Moving
forward, we believe these compounds are suitable for pre-
liminary toxicology testing. These studies will be an
essential component to further advance these OSCs as
potential anti-cancer therapeutics. Additionally, an
improved understanding of the pharmacokinetics of
these compounds may allow determination of the poten-
tial therapeutic index required for tumor specificity in
vivo. While our results indicate that micro-molar concen-
trations would be required to achieve apoptosis in leuke-
mic but not normal cells, the maximum achievable
plasma concentration of each compound has yet to be
determined. It is possible that a slightly less active com-
pound will have a higher achievable dose, making it more
suitable for further study. An alternative approach would
be sustained low-dose delivery, but the efficacy of this
approach for organosulfur compounds remains untested.
While compounds F, F1, H3, H7, K, N2, and Q are not
suitable for animal testing, the information gleaned by
comparing their activity to their structure will be impor-
tant for the development of new compounds. A new
round of structure-activity analysis based on these data
may lead to novel compounds with even higher tumor-
specific activity. It is interesting to note that the com-
pounds to move forward are not necessarily from one
structural class, and it will be fascinating to determine
exactly how and why the flanking regions alter potency
and specificity to such an extent.
In addition to yielding promising drug candidates, this
study also provides a model for academic drug discovery
and design. By integrating separate synthetic chemistry
and molecular biology laboratories remarkable progress
was achieved towards a novel therapeutic class.
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